Search

Your search keyword '"Kleijne, Jeroen A."' showing total 7 results
Start Over Author "Kleijne, Jeroen A."
7 results on '"Kleijne, Jeroen A."'

1. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase

Author

Ong, Andrew T.L., Serruys, Patrick W., Mohr, Frederick W., Morice, Marie-Claude, Kappetein, A. Pieter, Holmes, David R., Jr., Mack, Michael J., van den Brand, Joerg, Morel, Marie-Angele, van Es, Gerrit-Anne, Kleijne, Jeroen, Koglin, Joerg, and Russell, Mary E.

Subjects
Coronary heart disease -- Care and treatment, Coronary artery bypass -- Patient outcomes, Coronary artery bypass -- Research, Transluminal angioplasty -- Patient outcomes, Transluminal angioplasty -- Research, Stent (Surgery) -- Research, Health
Published
2006

2. Different cardiovascular profiles of three melanocortins in conscious rats; evidence for antagonism between γ2-MSH and ACTH-(1–24)

Author

Van Bergen, Patricia, Kleijne, Jeroen A, De Wildt, Dick J, and Versteeg, Dirk H G

Subjects
Male, endocrine system, integumentary system, Adrenalectomy, Blood Pressure, Peptide Fragments, Rats, Phenylephrine, Adrenocorticotropic Hormone, Adrenal Medulla, Heart Rate, alpha-MSH, Papers, Animals, Rats, Wistar, Drug Antagonism, hormones, hormone substitutes, and hormone antagonists
Abstract

1. We investigated the effects of [Nle4,D-Phe7]alpha-melanocyte-stimulating hormone (NDP-MSH), adrenocorticotropin-(1-24) (ACTH-(1-24)) and gamma 2-MSH, three melanocortins with different agonist selectivity for the five cloned melanocortin receptors, on blood pressure and heart rate in conscious, freely moving rats following intravenous administration. 2. As was previously found by other investigators as well as by us gamma 2-MSH, a peptide suggested to be an agonist with selectivity for the melanocortin MC3 receptor, caused a dose-dependent, short lasting pressor response in combination with a tachycardia. Despite the fact that NDP-MSH is a potent agonist of various melanocortin receptor subtypes, among which the melanocortin MC1 receptor, it did not affect blood pressure or heart rate, when administered i.v. in doses of up to 1000 nmol kg-1. 3. ACTH-(1-24) caused a dose-dependent decrease in blood pressure in combination with a dose-dependent increase in heart rate in a dose-range from 15 to 500 nmol kg-1. The cardiovascular effects of ACTH-(1-24) were independent of the presence of the adrenals. 4. Pretreatment with ACTH-(1-24) caused a pronounced, dose-dependent parallel shift to the right of the dose-response curve for the pressor and tachycardiac effects of gamma 2-MSH. The antagonistic effect of ACTH-(1-24) was already apparent following a dose of this peptide as low as 10 nmol kg-1, which when given alone had no intrinsic hypotensive activity. 5. These results form further support for the notion that it is not via activation of one of the as yet cloned melanocortin receptors that gamma-MSH-like peptides increase blood pressure and heart rate. The cardiovascular effects of ACTH-(1-24) seem not to be mediated by the adrenal melanocortin MC3 receptors, for which ACTH-(1-24) is a selective agonist, or by adrenal catecholamines. 6. There appears to be a functional antagonism between ACTH-(1-24) and gamma 2-MSH, two melanocortins derived from a common precursor, with respect to their effect on blood pressure and heart rate. Whether this antagonism plays a (patho)physiological role remains to be shown.

Published
1997

6. Effect of an anti-PDGF--receptor-blocking antibody on restenosis in patients undergoing elective stent placement

Author

Serruys, Patrick, Heyndrickx, Guy, Patel, Jatin, Cummins, Paul, Kleijne, Jeroen, and Clowes, Alexander

Abstract

AIM: The aim of the study was to determine whether a single intravenous infusion of 25mg/kg CDP860, a humanized di-Fab′ fragment against PDGF- receptor, leads to a reduction of in-stent restenosis. METHODS: In this phase II, double-blind, placebo-controlled, multicentre study 145 patients presenting with stable or unstable angina were randomized to a single infusion of placebo or active drug (CDP860) before undergoing stenting. Quantitative angiography and 3D intravascular ultrasound (IVUS) were obtained at baseline and follow-up. Primary endpoint was the IVUS assessment of percentage in-stent volume obstruction. RESULTS: At six-month follow-up, the placebo group and CDP860 group did not differ significantly regarding minimal luminal diameter (1.75±0.68 versus 1.82±­0.66mm), restenosis rate (16.2 versus 14.1%), minimal lumen area (4.71±1.85 versus 4.41±1.77mm 2 ), in-stent neointimal volume (30±23 versus 31±31mm 3 ) and in-stent obstruction volume (23.8± 14.4 versus 22.1±15.3%). Major adverse cardiac events at 210 days were similar in both groups: death 1.5 versus 1.4%, myocardial infarction 5.9 versus 8.1% and target vessel revascularization 16.4 versus 17.6%. CONCLUSION: A single intravenous administration of monoclonal antibody against PDGF- receptor failed to reduce the amount of neointimal hyperplasia after stent implantation. (Int J Cardiovasc Intervent 2003; 5: 214–222)

Published
2003
Full Text
View/download PDF

7. Effect of an anti-PDGF-beta-receptor-blocking antibody on restenosis in patients undergoing elective stent placement.

Author

Serruys PW, Heyndrickx GR, Patel J, Cummins PA, Kleijne JA, and Clowes AW

Subjects
Coronary Restenosis diagnostic imaging, Double-Blind Method, Female, Follow-Up Studies, Humans, Infusions, Intravenous, Male, Middle Aged, Time Factors, Ultrasonography, Interventional, Angina Pectoris therapy, Antibodies, Monoclonal, Coronary Restenosis prevention & control, Receptors, Platelet-Derived Growth Factor immunology, Stents
Abstract

Aim: The aim of the study was to determine whether a single intravenous infusion of 25 mg/kg CDP860, a humanized di-Fab' fragment against PDGF-beta receptor, leads to a reduction of in-stent restenosis., Methods: In this phase II, double-blind, placebo-controlled, multicentre study 145 patients presenting with stable or unstable angina were randomized to a single infusion of placebo or active drug (CDP860) before undergoing stenting. Quantitative angiography and 3D intravascular ultrasound (IVUS) were obtained at baseline and follow-up. Primary endpoint was the IVUS assessment of percentage in-stent volume obstruction., Results: At six-month follow-up, the placebo group and CDP860 group did not differ significantly regarding minimal luminal diameter (1.75 +/- 0.68 versus 1.82 +/--0.66 mm), restenosis rate (16.2 versus 14.1%), minimal lumen area (4.71 +/- 1.85 versus 4.41 +/- 1.77 mm(2) ), in-stent neointimal volume (30 +/- 23 versus 31 +/- 31 mm(3)) and in-stent obstruction volume (23.8 +/- 14.4 versus 22.1 +/- 15.3%). Major adverse cardiac events at 210 days were similar in both groups: death 1.5 versus 1.4%, myocardial infarction 5.9 versus 8.1% and target vessel revascularization 16.4 versus 17.6%., Conclusion: A single intravenous administration of monoclonal antibody against PDGF-beta receptor failed to reduce the amount of neointimal hyperplasia after stent implantation.

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results